CervoMed (CRVO)
NASDAQ:CRVO
Want to see CRVO full AI Analyst Report?
Top Page
CervoMed
(NASDAQ:CRVO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$4.00
▼(-0.99% Downside)
Action:ReiteratedDate:04/08/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and worsening cash burn) and a bearish technical setup (price below key moving averages and negative MACD). Offsetting this, recent positive clinical/program events provide meaningful pipeline momentum, while valuation inputs are largely neutral due to negative earnings and no dividend.
Positive Factors
Biomarker-driven Phase 2b results
Biomarker stratification and a defined target trough concentration materially improve trial design quality and probability of Phase 3 success. This durable scientific foundation supports patient enrichment, clearer endpoints, and a repeatable regulatory path if replicated, enhancing long-term program viability.
Negative Factors
No revenue; widening net losses
Persistent lack of product revenue combined with expanding net losses highlights dependence on external financing and successful trial outcomes. Over months, this undermines internal funding ability, forces focus on capital raises, and lengthens the path to self-sustaining operations absent clear commercialization milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Biomarker-driven Phase 2b results
Biomarker stratification and a defined target trough concentration materially improve trial design quality and probability of Phase 3 success. This durable scientific foundation supports patient enrichment, clearer endpoints, and a repeatable regulatory path if replicated, enhancing long-term program viability.
Read all positive factors
CervoMed (CRVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.41M
Dividend YieldN/A
Average Volume (3M)112.80K
Price to Earnings (P/E)―
Beta (1Y)-0.07
Revenue Growth-38.81%
EPS Growth-76.96%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.88
Shares Outstanding9,258,719
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)17.83
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue88.99
Enterprise Value/Gross Profit88.99
Enterprise Value/Ebitda-1.03
Forecast
1Y Price Target
$20.80Price Target Upside414.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.35
Revenue Forecast (FY)$425.00K
CervoMed Business Overview & Revenue Model
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the trea...
How the Company Makes Money
As a clinical-stage biotechnology company, CervoMed does not typically generate recurring product revenue and primarily funds operations through capital-raising activities. Based on publicly available high-level information, specific, itemized rev...
CervoMed Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -28.29M | -18.23M | -7.81M | -5.80M | -15.94M |
| Net Income | -26.97M | -16.29M | -2.17M | -5.80M | -24.10M |
Balance Sheet | |||||
| Total Assets | 23.40M | 43.08M | 9.97M | 4.16M | 37.84M |
| Cash, Cash Equivalents and Short-Term Investments | 20.86M | 38.92M | 7.79M | 4.09M | 37.31M |
| Total Debt | 0.00 | 0.00 | 0.00 | 12.41M | 0.00 |
| Total Liabilities | 5.18M | 3.88M | 2.60M | 13.16M | 2.93M |
| Stockholders Equity | 18.22M | 39.20M | 7.38M | -9.00M | 34.91M |
Cash Flow | |||||
| Free Cash Flow | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Operating Cash Flow | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Investing Cash Flow | 18.10M | -28.66M | 0.00 | 0.00 | 4.00K |
| Financing Cash Flow | 4.59M | 46.40M | 11.15M | 0.00 | 33.30M |
CervoMed Technical Analysis
Neutral
4.04
Price Trends
4.33
Negative
6.07
Negative
7.14
Negative
Market Momentum
-0.13
Negative
47.36
Neutral
46.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVO, the sentiment is Neutral. The current price of 4.04 is above the 20-day moving average (MA) of 3.98, below the 50-day MA of 4.33, and below the 200-day MA of 7.14, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 47.36 is Neutral, neither overbought nor oversold. The STOCH value of 46.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRVO.
CervoMed Risk Analysis
CervoMed disclosed 75 risk factors in its most recent earnings report. CervoMed reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CervoMed Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $347.77M | -2.24 | -129.98% | ― | 250.00% | 15.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $37.41M | -2.65 | -96.04% | ― | -38.81% | -76.96% | |
48 Neutral | $393.68M | -2.14 | -115.27% | ― | 2925.73% | -294.29% | |
45 Neutral | $33.33M | -3.48 | -88.89% | ― | 56.52% | 75.22% | |
42 Neutral | $29.40M | -0.46 | -191.12% | ― | ― | -24.38% |
* Healthcare Sector Average
CRVO
CervoMed
3.99
-5.81
-59.29%
XFOR
X4 Pharmaceuticals
4.14
-1.58
-27.62%
ABVC
ABVC BioPharma
1.23
0.37
43.02%
JSPR
Jasper Therapeutics
0.97
-3.01
-75.69%
PRLD
Prelude Therapeutics
4.43
3.62
446.91%
ESLA
Estrella Immunopharma
1.66
0.87
110.13%
CervoMed Corporate Events
Business Operations and StrategyProduct-Related Announcements
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
Positive
Apr 7, 2026
On April 7, 2026, CervoMed announced that its representatives would present key aspects of the neflamapimod clinical program at the 2026 Lewy Body Dementia Association Annual Meeting in Atlanta, highlighting clinical findings, global regulatory al...
Business Operations and StrategyRegulatory Filings and Compliance
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
Neutral
Mar 23, 2026
CervoMed Inc. has posted an investor presentation on its website under the Investors – Events and Presentations section, outlining summary information about its business, clinical studies, development plans and financial position intended to...
Business Operations and Strategy
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
Positive
Mar 19, 2026
On March 19, 2026, CervoMed reported new analyses from its Phase 2b RewinD-LB trial showing that DLB patients with lower plasma pTau181 levels, indicating absence of Alzheimer’s co-pathology and earlier-stage disease, experienced greater cli...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
Neutral
Mar 17, 2026
On March 17, 2026, CervoMed reported fourth quarter and full-year 2025 results alongside updates on its neflamapimod pipeline, highlighting positive Phase 2b RewinD-LB data in dementia with Lewy bodies presented in 2025 and regulatory alignment wi...
Business Operations and StrategyProduct-Related Announcements
CervoMed Advances Neflamapimod With Phase 1 Completion
Positive
Mar 4, 2026
On March 4, 2026, CervoMed reported completion of a Phase 1 healthy volunteer study assessing the pharmacokinetics of a new, stable crystal form of its lead drug neflamapimod, manufactured via a controlled process to avoid prior polymorph-related ...
Business Operations and Strategy
CervoMed’s Neflamapimod Added to U.K. ALS Platform
Positive
Feb 18, 2026
CervoMed Inc., a U.S.-based clinical-stage biotechnology company listed on Nasdaq, develops oral small-molecule therapies for age-related neurodegenerative disorders, led by neflamapimod. The drug candidate targets p38 MAP kinase–mediated ne...
Business Operations and StrategyRegulatory Filings and Compliance
CervoMed Releases Updated Investor Presentation and Business Overview
Neutral
Jan 8, 2026
On January 8, 2026, CervoMed Inc. disclosed that it has made an investor presentation available on its website under the “Investors – Events and Presentations” section, summarizing information about its business, clinical studies...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.